

Minutes
NSGO General Assembly
April 08, 2011, Holmen Fjordhotel, Oslo

1. The meeting was opened by the NSGO president Elisabeth Åvall Lundqvist.
2. Svein Vossli was elected chair of the meeting.
3. The meeting was declared to have been proclaimed in due order.
4. Kristina Hellman was elected secretary of the meeting.
5. Annika Auranen and Kahrine Woie were elected to check the minutes and to count votes.
6. NSGO President Elisabeth Åvall Lundqvist's annual report of 2010:

The Board received news that Mark Baekelandt would resume office autumn 2010 but the situation was not resolved. At the Board meeting January 14th 2011 Mark Baekelandt was released from office due to long-term health problems. The Vice-President was automatically installed as President. NSGO members were informed by e-mail in January 2011. The skills and expertise of Mark Baekelandt is highly appreciated and we thank Mark for all his work for the Society.

The annual meeting 2010 was held in Copenhagen with a symposium on Cervical cancer: State of the Art and new Insights. Thirteen new members were welcomed to our Society and new Board members were elected.

The NSGO Board has had seven Board meetings and two newsletters have been issued. During 2010 the Board has continued the work to achieve the goals set up at the Strategic meeting 2009. A new NSGO logo has been launched, the website has further been developed and the number of hits increased to 49 233, compared to 10 223 in May 2010. The Board propose a more simplified application for membership, addressed in § 16.

Due to more rigorous ethical rules of sponsorship to medical organizations the pharmaceutical companies may not offer sponsorship in a sum exceeding the cost of the professional conference. NSGO membership fee was therefore introduced 2010 but only 86 of 284 members have paid despite reminders. The Board anticipates more paying members the coming year.

During the year, NSGO has been active in clinical trials, GCIG and ENGOT. To increase collaboration between research nurses within the Nordic countries a session for study nurses has been arranged during this Annual meeting.

The NSGO-CTU is led by a Director responding to the NSGO Trial Unit Foundation, an independent and non-commercial institution consisting of a committee of 5 members appointed by the NSGO Board with a state-authorized accountant. Together with the NSGO Trial Unit Foundation the Board has outlined criteria of qualifications as NSGO-CTU medical director. The criteria was presented and will be posted on the website. The NSGO Foundation has prolonged the contract with Gunnar Kristensen as medical Director until April 1st, 2013.

7. The Clinical Trial Unit Director Gunnar Kristensen's annual report 2010:
8. The following *closed studies* were presented:
 - ICON 7 (A randomised, two-arm, multi-centre GCIG trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with EOC): Abstract submitted to ASCO 2011 presenting OS data.
 - Calypso study (A multinational, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (Caelyx®) and Carboplatin vs. Paclitaxel and Carboplatin in patients with EOC in late relapse (>6 months)): Several publications are coming with equally distribution of authorship. Four abstracts have been submitted to ASCO 2011.
 - Aurelia (Avastin plus single-agent chemotherapy in platinum-resistant ovarian cancer): All patients have been recruited and the study is closed. Results will be presented at ASCO 2012.
 - OVAR 9 (multi-national randomized Phase III GCIG Intergroup study comparing 1st line chemotherapy with Paclitaxel, Carboplatin and Gemcitabine vs. Paclitaxel and Carboplatin in previously untreated patients with EOC FIGO stages I-IV): Publications are coming with authorships according to recruitment.
 - OVAR 16 (study of pazopanib versus control as maintenance therapy after first-line paclitaxel-carboplatin in ovarian cancer): Closed for recruitment. Maintenance has been amended to 24 months.

Ongoing studies:

OVAR 12 (randomized phase III trial of BIBF1120 versus placebo in combination with and maintenance therapy after first-line paclitaxel-carboplatin in ovarian cancer): Recruitment is going well with 1000 patients included 1st April 2011. NSGO is leading recruitment with 248 patients. Recruitment will stop at the end of June.

New studies:

There are several new proposals, for example:

AMG 386 (AGO) 1st line on EOC stage III-IV with a new angiogenesis inhibitor, Angiopoetin (paclitaxel-carboplatin +/-Amg 386 (15mg/kvm) + 18 months maintenance with Amg 386 iv once weekly). Planned start 1st July 2011.

PARPinhibitor: Phase I trial of Olaparib in combination with carboplatin (AUC 4) and paclitaxel (175 mg/kvm). Start of recruitment planned late quarter 1 or 2 2012.

9. The accountancy and final accounts for 2010 were presented by our treasurer Mansoor Mirza. The economy of the Society is healthy. The final balance for 2010 was 882.219 DKK. In the final balance at December 31, 2010 the

bank account was 954.213 DKK because GSK of mistake made a payment of 71.994 DKK to the Society instead of to the CTU. In January 2011 the sum of 71.994 DKK was transferred from the Society to the NSGO CTU bank account.

10. The Accountants report (Bengt Sorbe and Tone Skeie Jensen): The year report of 2010 has been accepted by the official accountants, BDO ScanRevision signed by Statsautoriseret Peter Sandal Jeppesen. The accountancy and final accounts were found to be in due order.
11. The General Assembly adopted the accounts and the report and gave liability to the Board.
12. The President presented the outlines of planned NSGO activities for 2011:
 - Clarify the different ethical rules of sponsorship from pharmaceutical companies to medical organizations in Nordic countries and the implication on NSGO economy.
 - Continued work with implementation of new By-laws and simplification of membership applications. Evaluate membership status for current members who have not paid membership fees and who have no e-mail address.
 - Prepare for online voting of new Board members and President Elect according to Bylaws §6.
 - Continued development of the website, installation of the new webmaster Kasper Skriver Gravesen.
 - Collaboration with NSGO CTU Foundation Committee concerning NSGO-CTU medical director applications. The time for application is planned to be February 2012. Continued international collaboration and implementation of new studies by CTU.
 - Collect suggestions and proposals for FIGO revision of Ovarian and Fallopian Tube cancers Staging classification, to be sent to FIGO Committee latest Dec 5th 2011.
 - Prepare the 25th Anniversary of NSGO (2012)
 - The budget for 2011 was presented. A small deficit is anticipated due to changed rules of sponsorship.
13. The General Assembly approved the budget and it was decided to have an Annual Membership Fee of 25 Euro for 2012.
14. Seven new members were adopted and welcomed in the Society: Mika Helste, Sinikka Oksa, Riitta Koivisto-Korander and Annika Riska from Finland, Merete Paludan from Denmark, Thea Eline Hetland from Norway

and Åsa Åkesson from Sweden. The total number of members is now 291.

15. Election of accountants for 2011.
Bengt Sorbe and Tone Skeie Jensen were re-elected as accountants.
16. Election of Nominating Committée for 2011.
Nina Kjeldsen for Denmark, Päivi Vuolo-Merilä for Finland, Janne Kaern for Norway and Bengt Tholander for Sweden were re-elected as Nominating Committée.
17. Proposal by the NSGO Board for amendment of NSGO Bylaws to simplify application for membership. The Board considers that the required letter of recommendation, the mandatory personal presence as well as the acceptance of membership once a year is old fashion. The NSGO Board propose that the NSGO Board will constitute the membership committee and make decisions about membership at the Board meetings continuously. The following change is proposed to the Bylaws §3.3. *Application for membership is sent to the Board. A list of new members should be sent out with the call for the General Assembly. Membership is activated when accepted by the NSGO Board.*
18. Voting. The G.A accepted the amendment of NSGO Bylaws to simplify application for membership.
19. No further questions were raised.
20. Next meeting, presented by prof Johanna Mäenpää, will be held in Tampere, Finland, on the 26th-27th of April 2012 and will be the 25th anniversary of NSGO.
21. The General Assembly meeting was closed and delegates were thanked by Svein Vossli.

Kristina Hellman
Secretary General Assembly

Svein Vossli
Chairman General Assembly

Reviewed:

Reviewed:

Elisabeth Åvall Lundqvist
President

Kathrine Woie

Annika Auranen